
www.rakceramics.com

## RAK Ceramics PSC <br> 20151 Quarter Financial Results

- Reported revenue is higher by AED 3.3 mn to AED 744.1 mn in Q1 2015 compared to Q1 2014 of AED 740.8 mn . This revenue is excluding revenue of AED 29.9 mn (YoY AED 51.9 mn ) for discontinued operations (Sudan and RAK Pharma)
- Core revenue is lower by $5.8 \%$ at AED 656.2 mn compared to AED 696.9 mn YoY.
- Non-core revenue is higher by $22.8 \%$ at 117.8 mn compared to AED 95.9 mn YoY
- In spite of lower overall revenue, consolidated reported net profit in Q1 2015 is higher at AED $\mathbf{6 0 . 4} \mathbf{~ M n}$ compared to AED 58.7 mn YoY. Net profit margin is higher at $9.8 \%$ compared to $7.8 \%$ YoY.
- Better operating efficiency due to technology improvements and savings in procurement of raw materials resulted in improvement of core gross profit margin by $0.9 \%$ to $30.2 \%$
- EBITDA in Q1 2015 is AED 130.5 mn compared to AED 134.2 mn in Q1 2014.
- Adjusted net profit (excluding impact of Hyperinflation of AED 15.4 mn in Sudan and Iran) on a like to like basis is higher by $22.2 \%$ at AED 75.8 mn compared to AED 62.0 mn in Q1 2014.
- Profit from sale of investments in Laticrete RAK LLC (AED 37.6 mn ), RAK Pharma and Mosfly in Bangladesh, (AED 1.5 mn ) have been accounted for in Q1 2015
- SPA of RAK Sudan was executed in Mar' 15 end and the transaction is expected to be completed in Q2 '15. Impairment provision of AED 48.4 mn has been recognised in Q1 2015
- Net debt has reduced from AED 1.41 bn to AED 1.37 bn
- Euro depreciated nearly 10.5\% during the quarter resulting in Forex loss of AED 21.2mn compared to a gain of AED 2.6 mn in Q1 2014
- Hyperinflation from Sudan and Iran increased from AED 3.3 mn to AED 15.2 mn YoY
- Natural gas price in UAE increased by $12.5 \%$ quarter on quarter resulting in extra costs of AED 5.4 mn .
- Decrease in oil price has benefitted our European competitors which impacted realisations during the Quarter.
- Projects initiated to enhance branding and positioning, reengineer processes and integrate Europe
- 88 Kaizen AET teams now in place across the factories in UAE
- Cost savings from raw materials and freight procurement
- Forward hedging contract for Euro 20.0 mn to mitigate forex loss in future.
$\square$ Strengthened leadership team with six new senior appointments


## Executive Summary - Financial Performance

Overall revenue in Q1 2015 decreased by $2.4 \%$ to AED 774.1 mn . Core revenue decreased by $5.8 \%$ to AED 656.2 mn and Non-Core revenue increased by $22.8 \%$ to AED 117.8 mn . Tiles revenues decreased by $13 \%$ to AED 510.2 mn . SW revenue increased by $0.7 \%$ to AED 110.9 mn . RAK Porcelain has been consolidated from Q4 2014 and it is included in core. Reported net profit increased by $2.8 \%$ to AED 60.4 mn . Profit of AED 60.4 mn is after considering net loss of AED 9.3 mn on account of gain on sale of investments in Latircrete ( 37.6 mn ), RAK pharma and Moshfly (AED 1.5 mn ) and impairment provision of Sudan (AED 48.4 mn ) on executing SPA Adjusted Net Profit increased to AED 75.8 mn after adding AED 15.4 mn of Hyper inflation impact compared to AED 62.0 mn YoY. Total EBITDA decreased by $2.7 \%$ to AED 130.5 mn .



Total EBITDA: Core and Non-Core (AED mn)

$\square$ Non Core $\quad$ Core

## Core Revenues Breakdowns

On account of lower revenues in European countries due to currency depreciation, a refocused sales and distribution strategy in India and unusually high Q1/14 sales in Bangladesh from inventory liquidation, revenues from tiles fell in the quarter by $13 \%$ YoY to AED510.2 million. SW revenues increased by $0.7 \%$ to AED 110.9 mn .

| Tiles Revenue: By Production location |  |  |  |
| :---: | :---: | :---: | :---: |
| Tiles |  |  |  |
| (AED mn) | Q1 2014 | Q1 2015 | YoY Change |
| UAE | 381.5 | 351.2 | (30.3) |
| India | 104.4 | 97.4 | (7.0) |
| Bangladesh | 41.2 | 34.7 | (6.4) |
| China, Iran and Sudan | 67.6 | 38.3 | (29.3) |
| Total Gross | 594.6 | 521.5 | (73.1) |
| Less: Elimination | (7.8) | (11.3) | (3.5) |
| Total Net | 586.8 | 510.2 | (76.5) |


| Tiles Revenue: By End Markets |  |  |  |
| :--- | ---: | ---: | ---: |
| Tiles |  |  |  |
| (AED mn) | Q1 2014 | Q1 2015 | YOY Change |
| UAE | 109.7 | 120.3 | 10.6 |
| India | 103.8 | 93.6 | $(10.2)$ |
| Saudi Arabia | 85.2 | 84.7 | $(0.6)$ |
| Bangladesh | 41.2 | 34.7 | $(6.4)$ |
| Germany | 30.9 | 17.5 | $(13.4)$ |
| China, Iran and Sudan | 52.8 | 33.9 | $(18.9)$ |
| Rest of GCC | 32.9 | 24.5 | $(8.4)$ |
| Others | 130.3 | 101.1 | $(29.2)$ |
| Total | $\mathbf{5 8 6 . 8}$ | $\mathbf{5 1 0 . 2}$ | $\mathbf{( 7 6 . 5 )}$ |


| SW Revenue: By Production Location |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
|  | SWD |  |  |
| (AED mn) | Q1 2014 | Q1 2015 | YOY Change |
| UAE | 76.7 | 83.4 | 6.7 |
| India | 9.7 | 5.7 | $(4.0)$ |
| Bangladesh | 24.3 | 22.4 | $(1.9)$ |
| Total Gross | 110.7 | 111.4 | 0.7 |
| Less: Elimination | $(0.6)$ | $(0.5)$ | 0.1 |
| Total Net | $\mathbf{1 1 0 . 1}$ | $\mathbf{1 1 0 . 9}$ | $\mathbf{0 . 8}$ |


| SW Revenue: By End Markets |  |  |  |
| :--- | ---: | ---: | ---: |
| SWD |  |  |  |
|  | Q1 2014 | Q1 2015 | YOY Change |
| UAE | 31.5 | 32.6 | 1.1 |
| Bangladesh | 24.3 | 22.4 | $(1.9)$ |
| UK | 19.5 | 18.9 | $(0.6)$ |
| India | 9.7 | 5.8 | $(3.9)$ |
| Saudi Arabia | 6.4 | 7.8 | 1.4 |
| Rest of GCC | 2.2 | 4.1 | 1.9 |
| Jordan | 1.1 | 0.9 | $(0.2)$ |
| Italy | 3.5 | 5.3 | 1.8 |
| Germany | 0.7 | 0.5 | $(0.2)$ |
| Others | 11.2 | 12.6 | 1.4 |
| Total | $\mathbf{1 1 0 . 1}$ | $\mathbf{1 1 0 . 9}$ | $\mathbf{0 . 8}$ |

## Gross Profits Snapshot

Overall gross margin in YTD Mar 2015 is at par with YTD Mar-14. Core margins is increased from 29.3\% to 30.2\% while Non Core margins have decreased from $25.1 \%$ to $22.1 \%$. Overall tiles margin is $26.5 \%$ and SW margin is at same level YoY at 43.1\% Porcelain is consolidated from Q4 2014 and GP Margin during Q1 2015 is 56.1\%


|  | YTD -Mar-14 | YTD Mar 15 |
| :--- | ---: | ---: |
| UAE | $34.8 \%$ | $31.7 \%$ |
| B'desh | $31.3 \%$ | $33.7 \%$ |
| India* | $9.6 \%$ | $15.8 \%$ |
| China and Iran | $(60.8) \%$ | - |
| Total Gross Profit Margin | $\mathbf{2 6 . 5 \%}$ | $\mathbf{2 5 . 3 \%}$ |

Core Gross Margins: Tiles and SWD (\%)


|  | YTD -Mar- <br> 14 | YTD 15 |
| :--- | ---: | ---: |
| UAE | $42.2 \%$ | $42.6 \%$ |
| B'desh | $49.2 \%$ | $49.2 \%$ |
| India* | $32.0 \%$ | $22.5 \%$ |
| Total Gross Profit Margin | $\mathbf{4 3 . 1 \%}$ | $\mathbf{4 3 . 1 \%}$ |

## Summary Income statement

Reported net profit of YTD increased by $2.8 \%$ to AED 60.4 mn with margin increase from $7.4 \%$ to $7.8 .0 \%$. Adjusted net profit is AED 75.8 mn with margin increase from $7.8 \%$ to $9.8 \%$ \% on account of gain sales of stake in RAK Pharma, Moshfly and Laticrete. EBITDA margin is lower to $\mathbf{1 7 . 5 \%}$ at AED $\mathbf{1 3 0 . 5} \mathbf{~ m n . ~}$ During Q1 2014, provision of AED 19.1 mn was created while in Q1 2015 provision of AED 11.3 mn has been reversed.

| Income Statement (AED mn) |  |  |
| :---: | :---: | :---: |
| Particulars | YTD Mar 2014 | YTD Mar 2015 |
| Tiles Revenue | 594.6 | 521.6 |
| SW Revenue | 110.7 | 111.4 |
| Table Ware Revenue |  | 35.1 |
| Total Core Gross Revenue | 705.3 | 668.1 |
| Less:- Eliminations | (8.4) | (11.9) |
| Total Core Net Revenue | 696.9 | 656.3 |
| Total Non -Core Gross Revenue | 190.2 | 187.1 |
| Less:- Eliminations | (94.3) | (69.4) |
| Total Non- Core Net Revenue | 95.9 | 117.8 |
| Total Revenue | 792.7 | 774.1 |
| Less: Discontinued Operations | (51.9) | (29.9) |
| Reported Revenue | 740.8 | 744.1 |
| Tiles COGS | 404.7 | 370.1 |
| sw Cogs | 63.2 | 63.6 |
| Table Ware COGS |  | 15.4 |
| Non Core COGS | 143.4 | 144.9 |
| Less:- Eliminations | (83.8) | (65.0) |
| Total COGS-Net | 527.6 | 529.0 |
| Total Gross Profit | 213.2 | 215.1 |
| Gross Profit Margins (calculated on reported revenue excluding Sudan and |  |  |
| Pharma) | 28.8\% | 28.9\% |
| Selling, General and Admin Expenses | (158.7) | (175.5)* |
| Other Income | 15.3 | 16.8 |
| Share of Profits | 8.5 | 5.7 |
| EBIT | 78.3 | 62.1 |
| EBIT Margins | 9.9\% | 8.0\% |
| Net Finance costs | (10.0) | (31.1)** |
| Profit/Loss) on Monitory positions | 2.6 | (1.6) |
| Profit /(Loss) from discontinued operation | (5.8) | (1.3) |
| Profit on sale of investments- Laticrete, RAK Pharma and Moshfly |  | 39.1 |
| Profit Before Tax | 65.2 | 67.1 |
| Tax Expense | (6.5) | (6.7) |
| Profit for the period | 58.7 | 60.4 |
| Profit Margin( calculated on Total Revenue) | 7.4\% | 7.8\% |
| Adjusted Net Profit | 62.0 | 75.8 |

EBITDA Calculation (AED mn)

|  |  |  |
| :--- | ---: | ---: |
| Yet Profit Before Tax | $\mathbf{5 8 . 7}$ | $\mathbf{6 0 . 4}$ |
| Tax | 6.5 | 6.7 |
| Depreciation and Amortization | 40.5 | 44.3 |
| Finance expense (Net) | 9.5 | 8.1 |
| Provisions | 19.1 | $(11.3)$ |
| (Gain)/loss on disposals of |  |  |
| fixed assets and Investments | $(3.4)$ | $(2.3)$ |
| Loss on Net Monetary Position | 3.3 | 15.4 |
| Profit on Sale of Investments | 0.0 | 9.3 |
| EBITDA | $\mathbf{1 3 4 . 2}$ | $\mathbf{1 3 0 . 5}$ |
| EBITDA Margin ( calculated on |  |  |
| Total Revenue) | $18.1 \%$ | $17.5 \%$ |

Margin ( calculated on Total Revenue) - RAK Sudan and RAK Pharma numbers are reclassified ${ }^{\circ}$ into discontinciea operations for the both periods.
Company Confidential

## Balance Sheet Highlights

Net debt position decreased by AED 44.5 mn to AED 1.36 bn equivalent to 2.6x EBITDA due to better working capital management in Q1 2015. Total CAPEX for Q1 2015 amounted to AED 49.4mn.

| Working Capital (AED mn/Days) |  |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | :---: | :---: | :---: |
|  | Dec 14 | Days |  |  |  | 15 | Days |
|  | 937.4 | 110 | 973.8 | 118 |  |  |  |
| Trade Receivables ( Net of Provision) | 1139.4 | 180 | 1113.9 | 189 |  |  |  |
| Inventory (Net of Provision) | 292.8 | 35 | 310.2 | 37 |  |  |  |
| Due from Related Parties (J/V's) | 439.5 | 69 | 405.1 | 69 |  |  |  |
| Trade Payables |  |  |  |  |  |  |  |


| CAPEX (AED mn) |  |  |
| :--- | ---: | ---: |
| Capex for 2015 | FYE Dec 14 | YTD Mar 15 |
| RAKC UAE | 93.2 | 26.0 |
| Bangladesh | 19.7 | 14.5 |
| India | 19.3 | 1.5 |
| Other Core | 6.9 | 2.6 |
| Total Core | $\mathbf{1 3 9 . 1}$ | $\mathbf{4 4 . 6}$ |
| AHCC -Rough Grading | 141.8 | 4.8 |
| Other Non core | 1.4 | - |
| Total Non Core | $\mathbf{1 4 3 . 2}$ | $\mathbf{4 . 8}$ |
| Total CAPEX | $\mathbf{2 8 2 . 3}$ | $\mathbf{4 9 . 4}$ |


| Net Debt (AED mn) |  |  |
| :--- | ---: | ---: |
| Net Debt | Dec-14 | Mar 15 |
| Long Term Loan | $1,116.5$ | 809.3 |
| STL and TR | 630.8 | 1045.3 |
| Overdraft | 122.3 | 164.7 |
| Gross Debt | $\mathbf{1 , 8 6 9 . 6}$ | $\mathbf{2 0 1 9 . 3}$ |
| Cash and Bank* | $(458.4)$ | $(652.5)$ |
| Net Debt | $\mathbf{1 , 4 1 1 . 2}$ | $\mathbf{1 , 3 6 6 . 7}$ |
| Cost of Debt | $3.0 \%$ | $2.8 \%$ |
| Net Debt to EBITDA | 2.4 | 2.6 |
| *On loans outstanding |  |  |

## FINANCIAL STATEMENTS

## Consolidated Net Income

|  | YTD Mar-14 | YTD Mar-15 |
| :---: | :---: | :---: |
| Revenue | 740.8 | 744.1 |
| Cost of sales | (527.6) | (529.0) |
| Gross profit | 213.2 | 215.1 |
| Administrative and general expenses | (72.5) | (90.8)* |
| Selling and distribution expenses | (86.2) | (84.7) |
| Other income | 15.3 | 16.8 |
| Results from operating activities | 69.8 | 56.4 |
| Finance cost | (15.3) | (33.8) |
| Finance income | 5.3 | 2.6 |
| Share of profit in equity accounted investees | 8.5 | 5.7 |
| Gain on disposal of equity accounted investees |  | 38.5 |
| Gain on disposal of subsidiary |  | 0.6 |
| Loss on net monetary position | 2.6 | (1.6) |
| Tax (expense)/income | (6.5) | (6.7) |
| Profit From Continuing Operations | 64.5 | 61.7 |
| Profit/(Loss) from discontinued operation | (5.8) | (1.3) |
| Profit for the period | 58.7 | 60.4 |
| Profit attributable to: |  |  |
| Owners of the Company | 58.0 | 57.9 |
| Non-controlling interests | 0.7 | 2.5 |
| Profit for the period | 58.7 | 60.4 |
| Earning Per Share - Continuing Operations | 0.08 | 0.07 |
| Earning Per Share | 0.07 | 0.07 |

## Consolidated Balance Sheet



## Consolidated Cash Flow



## DISCLAIMER

This information contained in the enclosed presentation summarises preliminary and introductory information on RAK Ceramics PSC (the Company). This presentation has been prepared for information purposes only and is not and does not form part of or constitute any prospectus, offering memorandum or offering circular or offer for sale or solicitation of any offer to subscribe for or purchase or sell any securities nor shall it or any part of it form the basis of or be relied on in connection with any credit evaluation or third party evaluation of any securities or any offerings or contract or commitment whatsoever.

The information contained herein has been prepared by the Company. Some of the information relied on by the Company is obtained from sources believed to be reliable but does not guarantee its accuracy or completeness. All potential recipients of the enclosed presentation are expected to be aware that the information contained herein is preliminary as of the date hereof, supersedes any previous such information delivered and will be superseded by any such information subsequently delivered. The information contained herein is subject to change without notice. The Company is under no obligation to update or keep current the information contained herein. No person shall have any right of action (except in case of fraud) against the Company or any other person in relation to the accuracy or completeness of the information contained herein.

Some of the information in this presentation may contain projections or other forward-looking statements regarding future events or the future financial performance of The Company. These forward-looking statements include all matters that are not historical facts. The inclusion of such forward-looking information shall not be regarded as a representation by the Company or any other person that the objectives or plans of the Company will be achieved. Future events are subject to various risks which cannot be accurately predicted, forecasted or assessed. No assurance can be given that future events will occur or that the company's assumptions are correct. Actual results may differ materially from those projected and past performance is not indicative of future results. The Company undertakes no obligation to publicly update or publicly revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly all potential recipients are expected to conduct their own due diligence on the information provided.

These materials are confidential and are being submitted to selected recipients only for the purpose described above. They may not be taken away, reproduced (in whole or in part), distributed or transmitted to any other person without the prior written consent of the Company. These materials are not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation and must not be acted on or relied on by persons who are not relevant persons. If this presentation has been received in error it must be returned immediately to the Company.

